High Dose Aprotinin Reduces Prothrombin and Fibrinogen Conversion in Patients Undergoing Extracorporeal Circulation for Myocardial Revascularization

M Spannagl; W Dietrich; A Beck; W Schramm

doi:10.1055/s-0038-1648829

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1994; 72(01): 159-160
DOI: 10.1055/s-0038-1648829

Letter to the Editor

Schattauer GmbH Stuttgart

High Dose Aprotinin Reduces Prothrombin and Fibrinogen Conversion in Patients Undergoing Extracorporeal Circulation for Myocardial Revascularization

M Spannagl

University of Munich, Department of Medicine and German Heart Center Munich, Germany

,

W Dietrich

University of Munich, Department of Medicine and German Heart Center Munich, Germany

,

A Beck

University of Munich, Department of Medicine and German Heart Center Munich, Germany

,

W Schramm

University of Munich, Department of Medicine and German Heart Center Munich, Germany

› Author Affiliations

Abstract

PDF Download

PDF (153 kb)

References

References
1 Gebhard W, Tschesche H, Fritz H. Biochemistry of aprotinin and aprotinin-like enzymes. In: Barett A, Salvesen G. eds Protease Inhibitors. Amsterdam: Elsevier; 1986. pp 375-388
2 Dietrich W, Spannagl M, Jochum M, Wendt P, Schramm W, Barankay Y, Sebening F, Richter J. Influence of high dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anaesthesiology 1990; 73: 1119-1126
3 Kluft C. Pathomechanisms of defective hemostasis during and after extra-corporeal circulation: contact phase activation. In: Blood use in cardiac surgery Friedei N, Heitzer R, Royston D. eds Steinkopff Verlag; Darmstadt: 1991. pp 10-15
4 Lu H, Soria C, Commin P, Piwnica SJA, Schumann F, Regnier O, Legrand Y. Hemostasis in patients undergoing extracorporeal circulation: The effect of aprotinin (Trasylol). Thromb Haemost 1991; 66: 633-637
5 Lavee J, Savion N, Smelinsky A, Goor D, Mohr R. Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg 1992; 53: 477-481
6 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombinantithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106
7 Pelzer H, Schwarz A, Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-159
8 Lill H, Spannagl M, Trauner A, Schramm W, Schuller D, Ofenloch Haehnle B, Draeger B, Naser W, Dessauer A. A new immunoassay for soluble fibrin sensitively detects the activation state of blood coagulation in vivo. Blood Coag Fibrinol 1993; 4: 097-102
9 Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds LH. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 01-10
10 Teufelsbauer H, Proidl S, Havel M, Vukovic Th. Early activation of hemostasis during cardiopulmonary bypass: Evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost 1992; 68: 250-252
11 Edmunds LH. Blood-surface interaction during cardiopulmonary bypass. J Cardiac Surg 1993; 8: 404-410
12 Boisclair MD, Lane DA, Phillippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1+2. Thromb Haemost 1993; 70: 253-258
13 Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?. Thromb Haemost 1993; 70: 259-262